Clinical Trial Update: Dose Range Finding Study of MK-0941 in Patients With Type 2 Diabetes Mellitus on Insulin (MK-0941-007 AM3 EXT1 AM1)(TERMINATED) [Phase 2]

View source ↗

Summary

A Phase 2 dose-ranging study of MK-0941 in insulin-treated Type 2 diabetes mellitus was terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Type 2 Diabetes Mellitus

Drugs mentioned

• MK-0941

Snippet

Sponsor: Merck Sharp & Dohme LLC | Conditions: Diabetes Mellitus, Type 2 | Phase 2 | Status: TERMINATED | Results posted: 2012-09-03